A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Haemonetics Corporation Completes Move to New Manufacturing Facility in Clinton, PA

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has fully commenced operations at its new manufacturing Center of Excellence in Clinton, PA.

The custom-built facility occupies approximately 200,000 square feet at 1300 Clifford Ball Drive in Clinton Commerce Park near Pittsburgh International Airport. Haemonetics previously operated a manufacturing facility in nearby Leetsdale, PA since 1990.

Initial manufacturing began earlier this year at the Clinton site, where Haemonetics makes use of both resources from its previous facility in Leetsdale as well as new, advanced technology and manufacturing equipment to support demand for the production of critical disposables and consumables across Haemonetics’ Plasma and Hospital businesses. The Clinton facility also incorporates several environmentally-focused features, including smart controls on the HVAC systems, a recycled compressor heat system for more efficient temperature control and a closed loop process water system that allows for free process cooling in the winter months and reduced chemical treatment needs.

“Haemonetics has been part of the Pittsburgh area for more than 30 years, and our new, state of the art Clinton facility highlights the value we place in this region and the skilled team we’ve developed here,” said Christopher A. Simon, Haemonetics’ President and Chief Executive Officer. “This facility also underscores Haemonetics’ continued focus on operational excellence by investing in the resources we need to ramp up production with a quality-first mindset and deliver for our customers and the donors, patients, collection centers and hospitals counting on our solutions.”

Haemonetics conducts business in more than 90 countries and has approximately 2,800 global employees, with over 250 in the Pittsburgh area.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy